/Investor DB

Arboretum Ventures — 2022 Investments

4 investments dated 2022 · listed companies and verified rows first · show all

Boomerang Medicalboomerangmedical.cominSeries A · Nov 2022 · $15M✓ verified

Boomerang Medical develops a bioelectric neuromodulation device to treat bowel urgency symptoms in patients with ulcerative colitis and other inflammatory bowel disease.

BiotechDigital HealthMedical DevicesMountain View, US

Co-investorsHatteras Venture Partners

BrightSpecbrightspec.cominDec 2022

BrightSpec develops molecular rotational resonance (MRR) spectroscopy instruments and software that identify and quantify gas-phase molecules from complex mixtures without front-end separation.

BiotechDeep TechHardwareWaltham, US

Rick Gordon(CEO)inWalter Colsman(Executive Officer, Director)JAFFRAY WOODRIFF(Director)ROBERT LLOYD(Executive Officer, Director)THOMAS JONES(Director)DAVID MCDANIEL(Executive Officer, Director)

Co-investorsGenoa VenturesMedvest Capital

Cardiosensecardiosense.comin𝕏Series A · Dec 2022 · $15M

Cardiosense develops wearable sensing hardware and deep-learning algorithms that convert physiological signals into clinical insights for cardiovascular disease detection and management.

AI & Machine LearningDigital HealthHealthtechMedical DevicesChicago, US

Amit Gupta(Co-founder, Advisor)inMozziyar Etemadi(Co-founder, Head of AI)Omer Inan(Co-founder, Chief Scientific Officer)inAndrew Carek(Co-founder, Chief Technical Officer)inEric Meizlish(Chief Executive Officer)inJohn D. Martin(Chief Medical Officer)in

Co-investorsBayMed Venture PartnersBelal Badat VenturesBroadview VenturesCross-Border Impact VenturesHatteras Venture PartnersLaerdal Million Lives Fund+2 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Delphinus Medical Technologies

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.